Related references
Note: Only part of the references are listed.Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems
Lisa J. Herrinton et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Validation of rheumatoid arthritis diagnoses in health care utilization data
Seo Young Kim et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Increased prevalence of diastolic dysfunction in rheumatoid arthritis
Kimberly P. Liang et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics
Jeremy A. Rassen et al.
MEDICAL CARE (2010)
Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III
Michael L. Johnson et al.
VALUE IN HEALTH (2009)
Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis
Soko Setoguchi et al.
AMERICAN HEART JOURNAL (2008)
The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population
John M. Davis et al.
ARTHRITIS AND RHEUMATISM (2008)
Does tumor necrosis factor a inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Joachim Listing et al.
ARTHRITIS AND RHEUMATISM (2008)
Developments in post-marketing comparative effectiveness research
S. Schneeweiss
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis
S Bernatsky et al.
RHEUMATOLOGY (2005)
The risk of congestive heart failure in rheumatoid arthritis - A population-based study over 46 years
PJ Nicola et al.
ARTHRITIS AND RHEUMATISM (2005)
Comparison of coding of heart failure and Comorbidities in administrative and clinical data for use in outcomes research
DS Lee et al.
MEDICAL CARE (2005)
Targeted anticytokine therapy in patients with chronic heart failure - Results of the Randomized Etanercept Worldwide evALuation (RENEWAL)
DL Mann et al.
CIRCULATION (2004)
Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy
F Wolfe et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study
PC Souverein et al.
HEART (2004)
Trends in heart failure incidence and survival in a community-based population
VL Roger et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial
ES Chung et al.
CIRCULATION (2003)
Case reports of heart failure after therapy with a tumor necrosis factor antagonist
HJ Kwon et al.
ANNALS OF INTERNAL MEDICINE (2003)
Evaluating medication effects outside of clinical trials: New-user designs
WA Ray
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Inflammatory mediators and the failing heart - Past, present, and the foreseeable future
DL Mann
CIRCULATION RESEARCH (2002)
Inflammation and atherosclerosis
P Libby et al.
CIRCULATION (2002)
Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
B Bozkurt et al.
CIRCULATION (2001)
Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy
YY Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
